Armata Wins FDA Breakthrough Therapy Designation For AP-SA02 In Complicated SAB; Stock Up

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus ba

Armata Pharmaceuticals Inc. (ARMP) stock rose 11.52% on September 14, 2026, driven by positive sentiment and a new peer-reviewed study on its therapeutic bacteriophage Ar-KM. The company's AP-PA02 therapy has completed Phase 2 trials, and the study provides mechanistic insights, reducing perceived development risk. Despite negative profitability and low revenue, traders are focused on the company's catalysts and momentum.

Armata Pharmaceuticals (ARMP) shares rose 8% after the FDA granted Breakthrough Therapy designation to AP-SA02, a treatment for complicated bacteremia caused by S. aureus. The designation is based on Phase 1b/2a study data showing 100% clinical response in treated patients. The company aims to develop bacteriophage therapeutics for resistant bacterial infections.

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over availa

Armata Pharmaceuticals (NYSE American: ARMP) reported Q2 2026 results for the quarter ended June 30, 2026, with $2.5M grant and award revenue, R&D of about $7.6M, G&A of about $5.2M, and an operating loss of about $10.3M. The company said it submitted the Phase 3 protocol for AP-SA02 to the FDA, received Fast Track and an agreed pediatric study plan, and received an additional $2.5M non-dilutive DoD funding.

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update ​ LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnolo